R&D | April 23, 2026
Sanplatec selects Mitsubishi Chemical’s Zelas TPS for new cell culture tubes
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
Sanplatec is leading the industry in the field of containers and devices for cell culture and live transport
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Subscribe To Our Newsletter & Stay Updated
